<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898062</url>
  </required_header>
  <id_info>
    <org_study_id>21-10018-BO</org_study_id>
    <nct_id>NCT04898062</nct_id>
  </id_info>
  <brief_title>CRP-Apheresis for Attenuation of Pulmonary, MYocardial and/or Kidney Injury in COvid-19</brief_title>
  <acronym>CAPMYKCO</acronym>
  <official_title>Randomized, Controlled, Proof-Of-Concept Trial of CRP-Apheresis for Attenuation of Pulmonary MYocardial and/or Kidney Injury in COvid-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 'CAPMYKCO' study is a randomized controlled, open-label, single center proof of concept&#xD;
      trial. The aim of this study is to evaluate whether a CRP-apheresis in addition to the&#xD;
      current standard therapy is intended to mitigate the severity of the disease course of&#xD;
      SARS-CoV-2, especially with regard to tissue injury in the lungs, heart and kidneys and their&#xD;
      consequences.&#xD;
&#xD;
      CRP-apheresis should reduce the necessity for endotracheal intubation and mechanical&#xD;
      ventilation as well as the duration of non-invasive/invasive ventilation requirements&#xD;
      compared to the control group.&#xD;
&#xD;
      The influence of CRP-apheresis on the attenuation of pulmonary, myocardial and/or kidney&#xD;
      tissue injury as well as the course of the COVID-19 disease will also be demonstrated by&#xD;
      evaluating various biomarkers, several clinical scoring systems, and the duration of&#xD;
      intensive care medical treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prognostic value of C-reactive protein (CRP) in assessing disease progression in COVID-19&#xD;
      is well known: The steeper the CRP rise in the days after infection and the higher the CRP&#xD;
      concentration at hospitalization, the worse the prognosis. It is believed that CRP&#xD;
      concentration not only reflects tissue damage but also causally contributes to the severity&#xD;
      of the damage that occurs. CRP apheresis effectively limits CRP rise, which may lead to&#xD;
      improved prognosis. CRP apheresis is a therapeutic hemapheresis procedure that selectively&#xD;
      removes C-reactive protein from the patient's plasma. Other causal therapies for immediate&#xD;
      selective reduction of CRP in the acute phase of disease are not currently available.&#xD;
&#xD;
      In the planned 'CAPMYKCO' study, CRP-apheresis in addition to current standard COVID-19&#xD;
      therapy is expected to mitigate the severity of disease progression, particularly with regard&#xD;
      to tissue injury in the lungs, the heart and/or the kidneys and their respective clinical&#xD;
      consequences.&#xD;
&#xD;
      CRP-apheresis treatment in COVID-19 patients should reduce the necessity for endotracheal&#xD;
      intubation and the duration of non-invasive / invasive ventilation compared to the control&#xD;
      group.&#xD;
&#xD;
      The influence of CRP-apheresis on the course of the COVID-19 disease will also be&#xD;
      demonstrated by evaluating different organ biomarkers and the duration of intensive medical&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of non-invasive/ invasive ventilation [days, hrs]</measure>
    <time_frame>14 days</time_frame>
    <description>In the intervention group, a reduced duration of non-invasive/ invasive ventilation is expected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Necessity for endotracheal intubation</measure>
    <time_frame>14 days</time_frame>
    <description>In the intervention group, a reduced rate of endotracheal intubation is expected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of pulmonary injury</measure>
    <time_frame>14 days</time_frame>
    <description>Tissue injury of the lungs:&#xD;
Lung injury score*: scores &gt;=3 (≥2.5 if rapid deterioration) are part of the criteria used in the referral to extracorporeal membrane oxygenation in acute lung injury. Another interpretation of the score indicates that: ≥2.5 - severe lung injury or ARDS (acute respiratory distress syndrome).&#xD;
Horovitz-index [PaO2/FiO2]&#xD;
Neopterin (serum concentration) [ng/mL]&#xD;
Oxygen saturation [sO2%]&#xD;
Necessity for mechanical ventilation [y/n] *(JF Murray et al. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis;1988:138:720-3.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of myocardial injury</measure>
    <time_frame>14 days</time_frame>
    <description>Tissue injury of the heart:&#xD;
hs-Troponin I (serum concentration) [ng/mL] and its log area under curve (AUC) within 14 days&#xD;
Creatine kinase (serum concentration) [U/L]&#xD;
CK-MB fraction (CK-MB) (serum concentration) [U/L]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of kidney injury</measure>
    <time_frame>14 days</time_frame>
    <description>Tissue injury of the kidneys:&#xD;
Incidence of acute kidney injury (AKI) (defined by: RIFLE, KDIGO, AKIN criteria) [y/n]&#xD;
Creatinine (serum concentration) [mg/dL] [μmol/L]&#xD;
Albumine (serum concentration) [mg/dL]&#xD;
Estimated Glomerular filtration rate (eGFR) [mL/min/1.73 qm]&#xD;
Nephro-check (urine concentration) TIMP-2 (tissue inhibitor of metalloproteinase-2) [mg/L] and IGFBP-7 (insulin-like growth factor-binding protein 7) [mg/L]&#xD;
Proenkephalin (serum concentration) [pmol/L]&#xD;
Necessity for renal replacement therapy (RRT) within 14 days [y/n]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of other tissue injury</measure>
    <time_frame>14 days</time_frame>
    <description>Immune status and other tissue injury:&#xD;
C-reactive protein (CRP) [mg/L]&#xD;
Interleukin-6 (IL-6) [pg/mL]&#xD;
D-dimer [µg/mL]&#xD;
Ferritin [µg/L]&#xD;
Leukocytes [/nL]&#xD;
Lactate dehydrogenase (LDH) [U/L]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of intensive care unit stay</measure>
    <time_frame>Until hospital discharge assessed up to 14 days</time_frame>
    <description>In the intervention group, a shorter stay at the ICU is expected [days, hrs]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA-score (Sequential Organ Failure Assessment) score</measure>
    <time_frame>14 days</time_frame>
    <description>The Sequential Organ Failure Assessment score* ranges from 0 to +4 [0, +1, +2, +3, +4] with an increasing risk of death or prolonged intensive care unit stay.&#xD;
*(Vincent JL: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. In:Intensive Care Med 1996:22;707-10.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of expected and unexpected adverse effects of CRP-apheresis.</measure>
    <time_frame>14 days</time_frame>
    <description>In the intervention group, the absence of unexpected serious adverse effects is expected.&#xD;
Serious adverse events [y/n]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>CRP-apheresis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this group will undergo 4 apheresis treatments, each lasting 4-7 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomized to this group will not undergo a apheresis treatments. They will be treated according to the current conventional treatment concept for covid-19 disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRP-apheresis</intervention_name>
    <description>The major advantages of depleting C-reactive protein by therapeutic apheresis are the selective removal of the damaging agent by the highly specific ligand and the good controllability of the procedure, since the plasma can be passed over the column as often as necessary to achieve the desired reduction. In addition, treatment can be interrupted or discontinued at any time.</description>
    <arm_group_label>CRP-apheresis</arm_group_label>
    <other_name>CRP-depletion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed SARS CoV-2 infection (PCR-test)&#xD;
&#xD;
          -  Oxygen therapy (maximum 'high-flow' therapy)&#xD;
&#xD;
          -  CRP plasma concentration ≥ 25 mg/l&#xD;
&#xD;
          -  CRP increase ≥ 15mg/l within 48h after admission.&#xD;
&#xD;
          -  Completed informed consent and written informed consent.&#xD;
&#xD;
          -  Legal capacity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Pregnancy / lactation period&#xD;
&#xD;
          -  Invasive, mechanical ventilation&#xD;
&#xD;
          -  Extracorporeal membrane oxygenation (ECMO) support&#xD;
&#xD;
          -  Participation in other interventional trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Thielmann, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>West-German Heart and Vascular Center, University Duisburg-Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Thielmann, Prof.</last_name>
    <phone>+49201 723 84908</phone>
    <email>matthias.thielmann@uk-essen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wolfgang Ristau</last_name>
    <phone>+494201 723 84927</phone>
    <email>wolfgang.ristau@uk-essen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West-German Heart and Vascular Center, University Duisburg-Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Thielmann, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Mueller AA, Tamura T, Crowley CP, DeGrado JR, Haider H, Jezmir JL, Keras G, Penn EH, Massaro AF, Kim EY. Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients. Cell Rep Med. 2020 Nov 17;1(8):100144. doi: 10.1016/j.xcrm.2020.100144. Epub 2020 Oct 29.</citation>
    <PMID>33163981</PMID>
  </reference>
  <reference>
    <citation>Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, Berger JS. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021 Jun 14;42(23):2270-2279. doi: 10.1093/eurheartj/ehaa1103.</citation>
    <PMID>33448289</PMID>
  </reference>
  <reference>
    <citation>Kunze R. C-Reactive Protein: From Biomarker to Trigger of Cell Death? Ther Apher Dial. 2019 Dec;23(6):494-496. doi: 10.1111/1744-9987.12802.</citation>
    <PMID>31788974</PMID>
  </reference>
  <reference>
    <citation>Torzewski J, Heigl F, Zimmermann O, Wagner F, Schumann C, Hettich R, Bock C, Kayser S, Sheriff A. First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection. Am J Case Rep. 2020 Jul 14;21:e925020. doi: 10.12659/AJCR.925020.</citation>
    <PMID>32661220</PMID>
  </reference>
  <reference>
    <citation>Pepys MB. C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target? Eur Heart J. 2021 Jun 14;42(23):2280-2283. doi: 10.1093/eurheartj/ehab169.</citation>
    <PMID>33778886</PMID>
  </reference>
  <reference>
    <citation>Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988 Sep;138(3):720-3. Erratum in: Am Rev Respir Dis 1989 Apr;139(4):1065.</citation>
    <PMID>3202424</PMID>
  </reference>
  <reference>
    <citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996 Jul;22(7):707-10.</citation>
    <PMID>8844239</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Matthias Thielmann</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>CRP-apheresis</keyword>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

